Rong Wang, PhD
Senior Research Scientist in EpidemiologyDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Senior Research Scientist in Epidemiology
Biography
Dr. Wang is a cancer epidemiologist who studies the health outcomes and etiology of different types of cancers, especially hematopoietic malignancies. She is interested in the pattern of care, treatment and cost in older adults. She is also working on traffic exposure and genetic characteristics on the risk of cancer.
Last Updated on May 09, 2025.
Appointments
Chronic Disease Epidemiology
Senior Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- Yale University (2008)
Research
Copy Link
Overview
Medical Research Interests
Biostatistics; Chronic Disease; Epidemiology; Health Care; Neoplasms
Public Health Interests
Environmental Health; Cancer; Maternal & Child Health
ORCID
0000-0002-2169-4174
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rong Wang's published research.
Publications Timeline
A big-picture view of Rong Wang's research output by year.
Research Interests
Research topics Rong Wang is interested in exploring.
Xiaomei Ma, PhD
Nikolai Podoltsev, MD, PhD
Natalia Neparidze, MD
Amer Zeidan, MBBS, MD
Scott Huntington, MD, MPH, MSc
Jan Philipp Bewersdorf, MD, FACP
275Publications
19,345Citations
Neoplasms
Chronic Disease
Publications
2026
Demographic, birth, parental characteristics, and the risk of early‐onset colorectal cancer: A population‐based nested case‐control study in California
Siddique S, Wang R, Berardi D, Johnson C, Wiemels J, Metayer C, Ma X. Demographic, birth, parental characteristics, and the risk of early‐onset colorectal cancer: A population‐based nested case‐control study in California. Cancer 2026, 132: e70458. PMID: 42324895, PMCID: PMC13284631, DOI: 10.1002/cncr.70458.Peer-Reviewed Original ResearchThis study investigates early-onset colorectal cancer, showing male sex, Hispanic ethnicity, high birthweight, and older paternal age increase risk, while foreign-born mothers may reduce it.Migration‐Associated Variation in Gastric Cancer Risk in the United States: Implications for Risk Stratification
Hyun C, Wang R, Hong S, Zhang X, Shin J. Migration‐Associated Variation in Gastric Cancer Risk in the United States: Implications for Risk Stratification. International Journal Of Cancer 2026 PMID: 42252557, DOI: 10.1002/ijc.70552.Peer-Reviewed Original ResearchConceptsGastric cancer riskNon-Hispanic whitesGastric cancer incidenceCancer riskCancer incidenceState cancer registry dataCancer surveillance dataCancer registry dataKorean populationAge-adjusted incidenceAsian populationsEarly-life exposuresJoinpoint regressionLong disease latencyPopulation denominatorsMigrant studiesLow-incidence settingsRegistry dataRisk gradientVietnamese subgroupsIncidence patternsHigh-risk subgroupsU.S. populationSurveillance dataEarly-lifePotential benefits and harms of screening strategies for monoclonal gammopathy of undetermined significance in the US: A simulation study
Ahmad I, Wang R, Neparidze N, Lange J, Wang S. Potential benefits and harms of screening strategies for monoclonal gammopathy of undetermined significance in the US: A simulation study. Clinical Lymphoma Myeloma & Leukemia 2026 DOI: 10.1016/j.clml.2026.06.001.Peer-Reviewed Original ResearchConceptsMultiple myelomaMonoclonal gammopathyMM patientsScreening strategiesMGUS casesPotential harms of overdiagnosisRisk factorsEnd Results databasePotential harmHarms of overdiagnosisEarly detectionRisk of overdiagnosisBody mass indexHigh-risk individualsScreening benefitsMicro AbstractLack of evidenceScreening frequencyResults databasePremalignant conditionMGUSMM incidenceMass indexGeneral populationGammopathyImmunomodulatory Agent Adherence Trajectories and Survival Among Older Patients With Multiple Myeloma.
Wang R, Ji M, Neparidze N, Ma X, Chang S, Wang S. Immunomodulatory Agent Adherence Trajectories and Survival Among Older Patients With Multiple Myeloma. JCO Oncology Practice 2026, op2500615. PMID: 42081788, DOI: 10.1200/op-25-00615.Peer-Reviewed Original ResearchAltmetricConceptsPoor adherence groupMultiple myelomaAdherence groupIMiD treatmentCox proportional hazards regression modelsCharacteristics associated with adherenceProportional hazards regression modelsSEER-Medicare databaseNon-Hispanic black patientsNon-Hispanic white patientsHazards regression modelsAssociated with adherenceSurvival outcomesRenal failureImmunomodulatory agentsLogistic regression modelsSEER-MedicareOlder patientsWhite patientsBlack patientsBone diseaseGroup 3Comorbidity burdenPatientsComorbid conditionsIP80-14 ASSOCIATION BETWEEN GENOMIC CLASSIFIER SCORES AND INITIAL MANAGEMENT OF LOCALIZED PROSTATE CANCER IN A POPULATION-BASED COHORT IN THE UNITED STATES
Leapman M, Wang R, Sprenkle P, Kim I, Dinan M, Gross C, Ma X. IP80-14 ASSOCIATION BETWEEN GENOMIC CLASSIFIER SCORES AND INITIAL MANAGEMENT OF LOCALIZED PROSTATE CANCER IN A POPULATION-BASED COHORT IN THE UNITED STATES. Journal Of Urology 2026, 215: e1590. DOI: 10.1097/01.ju.0001191764.50307.1e.14.Peer-Reviewed Original ResearchConceptsMo1251 CARDIA GASTRIC ADENOCARCINOMA IN THE UNITED STATES: GEOGRAPHIC AND RACIAL/ETHNIC DISPARITIES IN INCIDENCE AND SURVIVAL ACROSS MULTIPLE SEER STATES
Hyun C, Hong S, Wang R, Shin J. Mo1251 CARDIA GASTRIC ADENOCARCINOMA IN THE UNITED STATES: GEOGRAPHIC AND RACIAL/ETHNIC DISPARITIES IN INCIDENCE AND SURVIVAL ACROSS MULTIPLE SEER STATES. Gastrointestinal Endoscopy 2026, 103: s-2633. DOI: 10.1016/s0016-5107(26)06160-2.Peer-Reviewed Original ResearchMo1251 CARDIA GASTRIC ADENOCARCINOMA IN THE UNITED STATES: GEOGRAPHIC AND RACIAL/ETHNIC DISPARITIES IN INCIDENCE AND SURVIVAL ACROSS MULTIPLE SEER STATES
Hyun C, Hong S, Wang R, Shin J. Mo1251 CARDIA GASTRIC ADENOCARCINOMA IN THE UNITED STATES: GEOGRAPHIC AND RACIAL/ETHNIC DISPARITIES IN INCIDENCE AND SURVIVAL ACROSS MULTIPLE SEER STATES. Gastroenterology 2026, 170: s-2633. DOI: 10.1016/s0016-5085(26)06229-3.Peer-Reviewed Original ResearchAcute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States
Bewersdorf J, Wang R, Mendez L, Mina A, Aguirre L, Stahl M, Zeidan A, Ma X, Podoltsev N. Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States. Cancer 2026, 132: e70415. PMID: 42033416, DOI: 10.1002/cncr.70415.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyeloproliferative DisordersRetrospective StudiesSulfonamidesTreatment OutcomeUnited StatesConceptsAcute myeloid leukemiaPost-MPN acute myeloid leukemiaLower-intensity therapiesAllo-HCTOverall survivalIntensive chemotherapyMyeloproliferative neoplasmsMyeloid leukemiaPatients treated with intensive chemotherapyProgression to acute myeloid leukemiaComplications of myeloproliferative neoplasmsAllogeneic hematopoietic cell transplantationTreatment of acute myeloid leukemiaMedian overall survivalBCL2 inhibitor venetoclaxHematopoietic cell transplantationEffective bridging therapyOutcomes of patientsInhibitor venetoclaxCurative optionHypomethylating agentsBridging therapyAML patientsCell transplantationTreatment eraComparative Effectiveness Analysis of Lobectomy and Limited Resection for Elderly Non-small Cell Lung Cancer Patients via Emulation
Wang J, Wang R, Ma S. Comparative Effectiveness Analysis of Lobectomy and Limited Resection for Elderly Non-small Cell Lung Cancer Patients via Emulation. ICSA Book Series In Statistics 2026, 417-431. DOI: 10.1007/978-3-032-06649-7_17.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLimited resectionOverall survivalAdjuvant radiotherapyAdjuvant chemotherapySurgical treatmentSurgical treatment of non-small cell lung cancerEarly-stage non-small cell lung cancerAssociated with significantly worse overall survivalNon-small cell lung cancer patientsTreatment of non-small cell lung cancerEarly-stage NSCLC patientsCell lung cancer patientsSignificantly worse overall survivalCell lung cancerLong-term outcomesLung cancer patientsRandomized clinical trialsResection armNSCLC patientsTreatment regimensElderly patientsResectionLung cancerWhole cohortOverestimation of multiple myeloma survival from cancer registry data
Huber J, Wang M, Wang R, Schoen M, Colditz G, Wang S, Chang S. Overestimation of multiple myeloma survival from cancer registry data. Journal Of The National Cancer Institute 2026, djag028. PMID: 41652897, PMCID: PMC12967285, DOI: 10.1093/jnci/djag028.Peer-Reviewed Original ResearchAltmetricConceptsSymptomatic MMMultiple myelomaFive-year relative survival estimatesSurvival statisticsCancer registry dataRelative survival estimatesMM managementPremalignant conditionSurveillance, EpidemiologyMultiple myeloma survivalRegistry dataMedian survivalMM survivalMyeloma survivalSEERPopulation levelSurvival estimatesSurvivalMyelomaMonthsStatisticallyInclusionEpidemiologyPatients
News
Copy Link
News
- October 28, 2025Source: Yale News
Study Reveals Demographic Disparities in Uptake of Colorectal Cancer Screenings
- October 27, 2025
New Study Highlights Need for Coordinated Approach to Stomach Cancer Screening and Prevention
- June 03, 2025Source: Yale News
Insights & Outcomes: Star Music, Kavli Kudos, and Summertime Heart Risks
- May 14, 2025
Faculty Research Awards Showcase YSPH Strengths in Science
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Locations
1 Church Street
Academic Office
Ste 200, Rm 225
New Haven, CT 06510